tbuckley/cabot-search huggingface dataset:
BIOMARKER AND CMR NEGATIVE CARDIAC NONAMYLOIDOTIC MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE (CIDD) AND RENAL AMYLOIDOSIS
Authors: George Bodziock, Robert Cornell, Stacey Goodman, Agnes Fogo, Robert Hoffman, Mark Lawson, Joseph Salloum, Rebecca Hung
Journal: Journal of the American College of Cardiology (2018)
A novel USP9X substrate TTK contributes to tumorigenesis in non-small-cell lung cancer
Authors: Xiangling Chen, Chengli Yu, Jing Gao, Hongwen Zhu, Binghai Cui, Tao Zhang, Yanting Zhou, Qian Liu, Han He, Ruoxuan Xiao, Ruimin Huang, Hua Xie, Daming Gao, Hu Zhou
Journal: Theranostics (2018)

The X-linked deubiquitinase, USP9X, is implicated in multiple cancers by targeting various substrates. Increased expression of USP9X is observed in non-small-cell lung cancer (NSCLC) and is correlated with poor prognosis. However, the molecular mechanism for USP9X regulation of tumor cell survival and tumorigenesis in NSCLC is less defined. Methods: In this study, chemical labeling, quantitative proteomic screening was applied to analyze A549 cells with or without USP9X RNA interference. Functional in vitro and in vivo experiments were performed to confirm the oncogenic effects of USP9X in NSCLC and to investigate the underlying mechanisms. Results: The resulting data suggested that dual specificity protein kinase TTK is a potential substrate of USP9X. Further experimental evidences confirmed that USP9X stabilized TTK via direct interaction and efficient deubiquitination of TTK on K48 ubiquitin chain. Moreover, knockdown of USP9X or TTK inhibited cell proliferation, migration and tumorigenesis, and the immunohistochemical analysis of clinical NSCLC samples showed that the protein expression levels of USP9X and TTK were significantly elevated and positively correlated in tumor tissues. Conclusions: In summary, our data demonstrated that the USP9X-TTK axis may play a critical role in NSCLC, and could be considered as a potential therapeutic target.
LEVELS OF NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL DO NOT NEGATIVELY IMPACT THE ABILITY OF THE PCSK9 INHIBITOR, EVOLOCUMAB, TO PROMOTE REGRESSION OF CORONARY ATHEROSCLEROSIS
Authors: Adam J. Nelson, Rishi Puri, Christie Ballantyne, Leslie Cho, Danielle Brennan, Helina Kassahun, Ransi Somaratne, Scott Wasserman, Steven Nissen, Stephen Nicholls
Journal: Journal of the American College of Cardiology (2018)
Knob protein enhances epithelial barrier integrity and attenuates airway inflammation
Authors: Sung Gil Ha, Mythili Dileepan, Xiao Na Ge, Bit Na Kang, Yana G. Greenberg, Amrita Rao, Girija Muralidhar, Lali Medina-Kauwe, Michael A. Thompson, Christina M. Pabelick, Scott M. O'Grady, Savita P. Rao, P. Sriramarao
Journal: Journal of Allergy and Clinical Immunology (2018)
Multicenter prospective study of switching from GnRH agonists to GnRH antagonist for patients with early stage of castration resistant prostate cancer as a second-line hormonal therapy.
Authors: Yumiko Yokomizo, Narihiko Hayashi, Akitoshi Takizawa, Kazuki Kobayashi, Jun-ichi Ohta, Kazuo Kitami, Takeshi Kishida, Futoshi Tsuchiya, Masahiro Yao, Hiroji Uemura
Journal: Journal of Clinical Oncology (2018)

183 Background: It was reported that GnRH antagonist could extend progression free survival for prostate cancer patients significantly longer than GnRH agonist in a first line hormonal therapy. However, the usefulness of switching from GnRH agonist to GnRH antagonist as a second hormonal therapy remains obscure. We performed a multicentral prospective study to investigate whether the switching from GnRH agonist to GnRH antagonist (degalerix) for patients with castration resistant prostate cancer (CRPC) as the 2nd line hormonal therapy was effective. Methods: 37 patients who were pathologically diagnosed as prostatic adenocarcinoma and developed CRPC after 1st line hormonal therapy with GnRH agonist plus anti-androgens were enrolled. After confirming anti-androgen withdrawal syndrome, they were treated with switching from GnRH agonists to degalerix. The primary endpoint was PSA response (PSA decline or up to 10% over baseline PSA). Secondary endpoints were the time to 25% PSA increase from the baseline (PSA response time), PSA progression free survival (PPFS), the time to treatment failure, cancer specific survival, radiographic PFS (rPFS), and safety. Results: Mean age was 76 years old, super high risk; 20 cases (54.1%), high risk; 11 cases (29.7%), intermediate risk; 5 cases (13.5%), low risk; one case (2.7%). PSA responder rate was 24.3% (9 cases). In responders, the median PSA response time was 5.75 months, the median PPFS was 1.77 months, and rPFS rate at 3 months was 96%. Regarding safety, only 2 cases (5.4%) showed G3 of AE. The PSA response had no relationship with the change of serum testosterone, LH nor FSH. Conclusions: The effectiveness of switching from GnRH agonist to GnRH antagonist showed to be limited. Although no predictive factor of the switching was recognized, some long-term responders were seen. We expect the possibility of switching to GnRH antagonist for patients in the early stage of CRPC, especially non-metastatic status. Clinical trial information: UNKNOWN.
Magnetic Macroporous Hydrogels as a Novel Approach for Perfused Stem Cell Culture in 3D Scaffolds via Contactless Motion Control
Authors: Lisa Rödling, Esther Magano Volz, Annamarija Raic, Katharina Brändle, Matthias Franzreb, Cornelia Lee‐Thedieck
Journal: Advanced Healthcare Materials (2018)

Abstract There is an urgent need for 3D cell culture systems that avoid the oversimplifications and artifacts of conventional culture in 2D. However, 3D culture within the cavities of porous biomaterials or large 3D structures harboring high cell numbers is limited by the needs to nurture cells and to remove growth‐limiting metabolites. To overcome the diffusion‐limited transport of such soluble factors in 3D culture, mixing can be improved by pumping, stirring or shaking, but this in turn can lead to other problems. Using pumps typically requires custom‐made accessories that are not compatible with conventional cell culture disposables, thus interfering with cell production processes. Stirring or shaking allows little control over movement of scaffolds in media. To overcome these limitations, magnetic, macroporous hydrogels that can be moved or positioned within media in conventional cell culture tubes in a contactless manner are presented. The cytocompatibility of the developed biomaterial and the applied magnetic fields are verified for human hematopoietic stem and progenitor cells (HSPCs). The potential of this technique for perfusing 3D cultures is demonstrated in a proof‐of‐principle study that shows that controlled contactless movement of cell‐laden magnetic hydrogels in culture media can mimic the natural influence of differently perfused environments on HSPCs.
STRAIN IMAGING TECHNIQUES TO PREDICT CARDIAC RESYNCHRONIZATION THERAPY RESPONSE: A HEAD-TO-HEAD COMPARISON OF CARDIAC MAGNETIC RESONANCE MYOCARDIAL TAGGING, FEATURE TRACKING AND SPECKLE TRACKING ECHOCARDIOGRAPHY
Authors: Alwin Zweerink, Wouter van Everdingen, Robin Nijveldt, Albert van Rossum, Odette A.E. Salden, Mathias Meine, Alexander Maass, Kevin Vernooy, Frederik de Lange, Pierre Croisille, Patrick Clarysse, Bastiaan Geelhoed, Michiel Rienstra, Isabelle Van Gelder, Marc Vos, Maarten Jan Cramer, Cornelis Allaart
Journal: Journal of the American College of Cardiology (2018)
Native T1 and Extracellular Volume in Transthyretin Amyloidosis
Authors: Ana Martinez-Naharro, Tushar Kotecha, Karl Norrington, Michele Boldrini, Tamer Rezk, Candida Quarta, Thomas A. Treibel, Carol J. Whelan, Daniel S. Knight, Peter Kellman, Frederick L. Ruberg, Julian D. Gillmore, James C. Moon, Philip N. Hawkins, Marianna Fontana
Journal: JACC. Cardiovascular imaging (2018)
Sustained Id2 regulation of E proteins is required for terminal differentiation of effector CD8+ T cells
Authors: Kyla D. Omilusik, Marija S. Nadjsombati, Laura A. Shaw, Bingfei Yu, J. Justin Milner, Ananda W. Goldrath
Journal: The Journal of Experimental Medicine (2018)

CD8+ T cells responding to infection differentiate into a heterogeneous population composed of progeny that are short-lived and participate in the immediate, acute response and those that provide long-lasting host protection. Although it is appreciated that distinct functional and phenotypic CD8+ T cell subsets persist, it is unclear whether there is plasticity among subsets and what mechanisms maintain subset-specific differences. Here, we show that continued Id2 regulation of E-protein activity is required to maintain the KLRG1hi CD8+ T cell population after lymphocytic choriomeningitis virus infection. Induced deletion of Id2 phenotypically and transcriptionally transformed the KLRG1hi “terminal” effector/effector-memory CD8+ T cell population into a KLRG1lo memory-like population, promoting a gene-expression program that resembled that of central memory T cells. Our results question the idea that KLRG1hi CD8+ T cells are necessarily terminally programmed and suggest that sustained regulation is required to maintain distinct CD8+ T cell states.
DIFFERENCES IN CLINICAL OUTCOMES AND ECHOCARDIOGRAPHIC PROFILES OF PATIENTS WITH ATRIAL FIBRILLATION IN MEDICALLY-MANAGED SEVERE AORTIC STENOSIS AND PRESERVED LEFT VENTRICULAR EJECTION FRACTION
Authors: Nicholas Ngiam, Yong-Qiang Benjamin Tan, Ching-Hui Sia, Hui-Wen Sim, Nicholas Chew, William K.F. Kong, Edgar Tay, Kian Keong Poh
Journal: Journal of the American College of Cardiology (2018)
Omega-3 polyunsaturated fatty acids improve lipid profile and lower blood viscosity in CAPD patients.
Authors: B.A.C. van Acker, H.J.G. Bilo, C. Popp-Snijders, H. van Bronswijk, C. Rustemeijer, P.L. Oe, A.J.M. Donker
Journal: Kidney International (1987)
Comparison of Residual Risk–Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies
Authors: Wei Wei, Tomoko Kurita, Kenneth R. Hess, Tara Sanft, Borbala Szekely, Christos Hatzis, Lajos Pusztai
Journal: JAMA Oncology (2018)

<h3>Importance</h3> Many large adjuvant clinical trials end up underpowered because of fewer than expected events in the control arm. Ensuring a minimum number of events would result in more informative trials. <h3>Objective</h3> To calculate individualized residual risk estimates using residual risk prediction software and assess whether defining eligibility based on a minimum residual risk threshold could increase the reliability of clinical trial power calculations compared with eligibility criteria based on tumor size and nodal status. <h3>Design, Setting, and Participants</h3> We estimated residual risk in 443 consecutive patients with early-stage breast cancer and assessed clinical trial power as a function of residual risk distribution among the accrued patients. We defined residual risk as the risk of recurrence that remains despite receipt of standard-of-care therapy; this risk is determined by baseline prognostic risk and by the improvement from adjuvant therapy. We performed trial simulations to examine how the power of a 2-arm, 1:1 randomized clinical trial would change as the residual risk distribution of the trial population that met eligibility criteria based on tumor size and nodal status changes. We also simulated trials that use a minimum residual risk value as eligibility criterion. <h3>Main Outcomes and Measures</h3> Residual risk; clinical trial power as a function of residual risk distribution among the patients. <h3>Results</h3> In the 443 patients (mean [SD] age, 56.1 [12.3] years; range, 23-89 years), baseline prognostic and residual risks differed substantially: 328 (74%) patients had more than 20% baseline risk of recurrence; however, after adjustment for treatment effect only 12 (27%) had more than 20% residual risk. We assessed residual risk distribution in patient cohorts that met tumor size– and nodal status–based eligibility criteria for 3 currently accruing randomized adjuvant trials; the median residual risks were 28% (interquartile range [IQR], 25%-31%), 22% (IQR, 15%-28%), and 22% (IQR, 15%-28%), respectively, indicating that the power of these trials could vary unpredictably. Simulations showed that trials that use anatomical risk–based eligibility criteria can become underpowered if they accrue patients with low residual risk despite all participants meeting eligibility requirements. Using a minimum required residual risk threshold as eligibility criterion produced more reliable power calculations. <h3>Conclusions and Relevance</h3> When tumor size and nodal status are used to determine trial eligibility, the residual risk of recurrence can vary broadly, leading to unstable power estimates. The success of future adjuvant trials could be improved by defining patient eligibility based on a minimal residual risk of recurrence, and these trials can achieve a prespecified power with smaller sample sizes.
Incidental Detection of Type B2 Thymoma on 68Ga-Labeled Prostate-Specific Membrane Antigen PET/CT Imaging
Authors: Venkata Subramanian Krishnaraju, Rajender Kumar Basher, Harmandeep Singh, Shrawan Kumar Singh, Amanjit Bal, Bhagwant Rai Mittal
Journal: Clinical Nuclear Medicine (2018)

Abstract 68 Ga-labeled prostate-specific membrane antigen is a novel radiotracer for imaging of prostate cancer. We report a hormonally treated patient with prostate carcinoma, presenting with lower urinary tract symptoms and rising prostate-specific antigen levels, who underwent 68 Ga-labeled prostate-specific membrane antigen PET/CT for suspected recurrence. No tracer avid lesion was noted in the prostate gland and locoregional area. However, intense tracer avid heterogeneously enhancing soft tissue lesion with cystic areas and coarse calcifications was seen in the anterior mediastinum. PET/CT-guided biopsy from the mediastenal lesion revealed type B2 thymoma.
NHS in Scotland must face up to “difficult decisions” to remain sustainable
Authors: Bryan Christie
Journal: BMJ (2018)

Time is rapidly running out for Scotland to develop and implement solutions that will create a sustainable health service, a high level report warns.

The report,1 from the Royal College of Physicians of Edinburgh and the Good Governance Institute, makes key recommendations for securing the NHS’s future in Scotland, including difficult decisions about what the NHS can afford in the future.

The review was produced after …
INITIAL DATA FROM THE US PULMONARY HYPERTENSION REGISTRY: GENETICS AND DEMOGRAPHICS IN NEWLY DIAGNOSED PULMONARY ARTERIAL HYPERTENSION (PAH)
Authors: Raymond Benza, Adaani Frost, Greg Elliott, Eric Austin, David Badesch, Harrison Farber, Wendy Chung, Abby Poms, Kathy Feldkircher, Chang Yu, Jessica Badlam, Michael Pauciulo, William Nichols
Journal: Journal of the American College of Cardiology (2018)
Consultants condemn plans to link remuneration with management targets
Authors: Helen Jaques
Journal: BMJ (2013)

Consultants have voiced their disapproval of plans to link their pay progression and clinical excellence awards to local management targets.

The Review Body on Doctors and Dentists’ Remuneration (DDRB) has recommended that consultants’ pay progression and the granting of local excellence awards should be linked to performance and appraisal.12 Some of the measures against which performance would be judged would be the results that doctors achieve against their …
Race equality in the NHS
Authors: Abi Rimmer
Journal: BMJ (2017)

This month NHS England reported on how work to improve race equality in NHS trusts has been going.1

NHS staff from black and minority ethnic (BME) backgrounds are much more likely to be disciplined than white staff. In 74% of the 224 trusts analysed, BME staff were more likely to enter the disciplinary process than white staff. In London, BME …
Caught in a Bind
Authors: Catherine C. Motosko, Miriam Keltz Pomeranz, Alexes Hazen
Journal: JAMA Dermatology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria
Authors: L. Curto-Barredo, J. Spertino, I. Figueras-Nart, V. Expósito-Serrano, A. Guilabert, G. Melé-Ninot, X. Cubiró, M. Bonfill-Ortí, J. Garcias-Ladaria, M. Villar, X. García-Navarro, I. Bielsa-Marsol, M. Vilavella, G. Aparicio, C. Baliu-Piqué, A. Álvarez, N. Lamas-Domenech, X. Duran-Jordà, E. Serra-Baldrich, A. Giménez-Arnau
Journal: British Journal of Dermatology (2018)
Be prepared to work hard at admission
Authors: Dee Singh
Journal: BMJ (2006)

In answer to the question in Advice Zone, if you really have your mind set on medical school, then be prepared for some hard work and discouragement from others.1

Your situation and desire to train as a doctor are far from unique, and although requiring immense effort, it is still possible to gain admission to medical school. Without an honours degree in nursing you are ineligible for graduate entry courses, and regular five year courses might …
Abstract P6-06-03: Withdrawn
Authors: C Cruz, S Bonache, G Montalban, M Castroviejo-Bermejo, A Llop-Guevara, A Vivancos, C Saura, J Arribas, O Díez, V Serra, S Gutiérrez-Enríquez, J Balmaña
Journal: Cancer Research (2018)

Abstract This abstract was withdrawn by the authors.
DRUG ELUTING STENTS VERSUS BARE METAL STENTS IN SAPHENOUS VEIN GRAFT INTERVENTION: AN UPDATED META-ANALYSIS OF RANDOMIZED TRIALS
Authors: Varunsiri Atti, Nileshkumar J. Patel, Chirag Bavishi, Avnish Tripathi, Nikhil Nalluri, Mauricio G. Cohen, Annapoorna S. Kini, Samin K. Sharma, Deepak L. Bhatt, George Dangas
Journal: Journal of the American College of Cardiology (2018)
Questions About Emergency Department Treatment of Patients With Solid Tumors and Hematological Malignant Neoplasms
Authors: Emmanuelle Zamparini, Ida Pavese, François Vincent
Journal: JAMA Oncology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Is there an age limit for house officer posts?
Authors: Simon Eccles
Journal: BMJ (2004)

<i>Got a career or related problem that needs answering? Can9t find the right person to point you in the right direction? Log on to the Advice Zone (www.bmjcareers.com/advicezone) for reliable medical careers advice. You can post a question or see if one of our 300 advisers has already answered a similar question. Here is a selection of questions and answers posted on the site.</i>
BMJ Careers launches job review tool for doctors
Authors: Abi Rimmer
Journal: BMJ (2014)

Doctors can now review their jobs and rotations using a new tool launched by BMJ Careers. 

BMJ Careers Job Reviews (jobreviews.bmj.com) allows doctors of all grades to review their rotations, posts, and jobs. The reviews will give colleagues a detailed and realistic view of medical roles and rotations. Doctors can currently search for a hospital or a local education and training board (LETB) in England, and …
Bioactive Scaffolds for Regeneration of Cartilage and Subchondral Bone Interface
Authors: Cuijun Deng, Huiying Zhu, Jiayi Li, Chun Feng, Qingqiang Yao, Liming Wang, Jiang Chang, Chengtie Wu
Journal: Theranostics (2018)

The cartilage lesion resulting from osteoarthritis (OA) always extends into subchondral bone. It is of great importance for simultaneous regeneration of two tissues of cartilage and subchondral bone. 3D-printed Sr5(PO4)2SiO4 (SPS) bioactive ceramic scaffolds may achieve the aim of regenerating both of cartilage and subchondral bone. We hypothesized that strontium (Sr) and silicon (Si) ions released from SPS scaffolds play a crucial role in osteochondral defect reconstruction. Methods: SPS bioactive ceramic scaffolds were fabricated by a 3D-printing method. The SEM and ICPAES were used to investigate the physicochemical properties of SPS scaffolds. The proliferation and maturation of rabbit chondrocytes stimulated by SPS bioactive ceramics were measured in vitro. The stimulatory effect of SPS scaffolds for cartilage and subchondral bone regeneration was investigated in vivo. Results: SPS scaffolds significantly stimulated chondrocyte proliferation, and SPS extracts distinctly enhanced the maturation of chondrocytes and preserved chondrocytes from OA. SPS scaffolds markedly promoted the regeneration of osteochondral defects. The complex interface microstructure between cartilage and subchondral bone was obviously reconstructed. The underlying mechanism may be related to Sr and Si ions stimulating cartilage regeneration by activating HIF pathway and promoting subchondral bone reconstruction through activating Wnt pathway, as well as preserving chondrocytes from OA via inducing autophagy and inhibiting hedgehog pathway. Conclusion: Our findings suggest that SPS scaffolds can help osteochondral defect reconstruction and well reconstruct the complex interface between cartilage and subchondral bone, which represents a promising strategy for osteochondral defect regeneration.